For over 10 years at Pullan Consulting, Linda Pullan has been helping in identification, evaluation, valuation, negotiation and strategy for partnering, in or out. She has an extensive deal sheet from company acquisitions to Phase III to preclinical candidates to technologies.
After a Ph.D. in Biochemistry, Linda has over 20 years of industry experience, starting in drug discovery at Monsanto/Searle/Pfizer and ICI/Zeneca/AstraZeneca. She led teams that put Seroquel, a multi-billion dollar antipsychotic, and other molecules into development. Business development began with in-licensing technology and early drug candidates at AstraZeneca, and continued as head of oncology hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development, focusing on out-licensing. She also served as CEO of Viriome and on boards for Paloma and IRAD. Linda has spoken at many meetings, published papers and chapters.
She writes a free monthly newsletter Pullan’s Pieces (sign up on www.PullanConsulting.com ), for thousands of readers. Linda has webinars and whitepapers on partnering https://resources.sharevault.com/pullan-resource-series